CDK1 and neoplasm: In addition, ERCC6L, as a tumor promoter, could promote the proliferation, migration and invasion of breast cancer cells and accelerate cell cycle progression by activating the PLK/CDC25C/CDK1/Cyclin B and p53/p21/CDK1/Cyclin B signalling pathways.